Cargando…

Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients, including those who relapsed after transplant. However, the duration of remission requires improvements. Whether bridging to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Xing-yu, Zhang, Jian-ping, Zhao, Yan-li, Xiong, Min, Zhou, Jia-rui, Lu, Yue, Sun, Rui-juan, Wei, Zhi-jie, Liu, De-yan, Zhang, Xian, Yang, Jun-fang, Lu, Peihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352576/ https://www.ncbi.nlm.nih.gov/pubmed/37469510 http://dx.doi.org/10.3389/fimmu.2023.1191382

Ejemplares similares

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Yang, Junfang, et al.
Publicado: (2023)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
por: Xu, Qianwen, et al.
Publicado: (2023)

Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT
por: Liu, Sining, et al.
Publicado: (2020)

GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
por: Wang, Dongyao, et al.
Publicado: (2022)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt’s lymphoma: a case report
por: Cheng, Ling, et al.
Publicado: (2022)

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

Successful Treatment of Relapsed Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report
por: Pi, Yubo, et al.
Publicado: (2022)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Liu, Yadan, et al.
Publicado: (2021)

P1170: CAR-T THERAPY IS EFFECTIVE AND SAFE IN TREATING RELAPSED/REFRACTORY LYMPHOMA WITH MALIGNANT SEROUS CAVITY EFFUSION
por: Huang, Lefu, et al.
Publicado: (2023)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
por: Zhang, Xian, et al.
Publicado: (2023)

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
por: Zhao, Houli, et al.
Publicado: (2020)

The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
por: Lange, Andrzej, et al.
Publicado: (2018)

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
por: Kenkel, Troy J., et al.
Publicado: (2023)

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia
por: Zhao, Yan-Li, et al.
Publicado: (2021)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study
por: Lu, Yue, et al.
Publicado: (2023)

Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
por: Lange, Andrzej, et al.
Publicado: (2018)

Patient‐based prediction algorithm of relapse after allo‐HSCT for acute Leukemia and its usefulness in the decision‐making process using a machine learning approach
por: Fuse, Kyoko, et al.
Publicado: (2019)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report
por: Wang, Dongmei, et al.
Publicado: (2018)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.
por: Sannipoli, Daniele, et al.
Publicado: (2023)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
por: Zhang, Li-Na, et al.
Publicado: (2018)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Clinical study of late-onset hemorrhagic cystitis after allo-HSCT without in vitro T-cell depletion
por: Yuan, Hailong, et al.
Publicado: (2022)

Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
por: Zhang, Na, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oma975jh2ojt5qc6491ti95m02